Provided by Tiger Trade Technology Pte. Ltd.

Century Therapeutics, Inc.

0.7470
+0.079611.93%
Volume:954.20K
Turnover:693.88K
Market Cap:65.29M
PE:-2.39
High:0.7499
Open:0.6790
Low:0.6651
Close:0.6674
52wk High:1.19
52wk Low:0.3418
Shares:87.41M
Float Shares:46.13M
Volume Ratio:10.77
T/O Rate:2.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3127
EPS(LYR):-1.6093
ROE:-14.24%
ROA:-4.47%
PB:0.37
PE(LYR):-0.46

Loading ...

Century Therapeutics CEO Brent Pfeiffenberger Reports Acquisition of Common Shares

Reuters
·
Yesterday

Century Therapeutics Inc Files Initial Statement of Beneficial Ownership for Director Han Myung Lee

Reuters
·
Dec 12

Century Therapeutics Appoints Han Lee and Martin Murphy to Board

Reuters
·
Dec 09

Press Release: Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors

Dow Jones
·
Dec 09

We're Keeping An Eye On Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Simply Wall St.
·
Nov 30

Century Therapeutics CEO Brent Pfeiffenberger Reports Acquisition of Common Shares

Reuters
·
Nov 21

Century Therapeutics CEO Makes Significant Stock Sale!

TIPRANKS
·
Nov 20

Century Therapeutics Shares Fall After Leerink Partners Downgrade

MT Newswires Live
·
Nov 18

Century Therapeutics (IPSC) Gets a Buy from Clear Street

TIPRANKS
·
Nov 17

Leerink Partners Downgrades Century Therapeutics to Market Perform From Outperform

MT Newswires Live
·
Nov 17

Century Therapeutics Q3 net loss widens, despite lower costs

Reuters
·
Nov 13

Century Therapeutics reports Q3 EPS (40c) vs (37c) last year

TIPRANKS
·
Nov 13

Century Therapeutics Q3 EPS $(0.40) Misses $(0.34) Estimate

Benzinga
·
Nov 13

BRIEF-Century Therapeutics Q3 Net Income USD -34.422 Million

Reuters
·
Nov 13

Century Therapeutics Q3 Operating Income USD -36.124 Million

THOMSON REUTERS
·
Nov 13

Century Therapeutics Inc - Estimates Cash Runway Into 4Q 2027

THOMSON REUTERS
·
Nov 13

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Nov 13

Century Therapeutics Reports Preclinical Success for Immune-Evasive Beta Islet Therapy in Type 1 Diabetes

Reuters
·
Nov 13

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

THOMSON REUTERS
·
Nov 13

Century Therapeutics Inc - Ind-Enabling Studies to Start by Year-End 2025, Ind Submission Planned as Early as 2026

THOMSON REUTERS
·
Nov 13